DiaSys Diagnostic Systems GmbH

Alte Strasse 9
Holzheim,  65558

Germany
https://www.diasys-diagnostics.com/service-area/aacc-2023

• Booth: 2567

Since 1991, DiaSys Diagnostic Systems has been a leading and reliable specialist in developing and manufacturing diagnostic system solutions for small up to medium-sized labs. In line with strong commitment to quality, service, ease of use and sustainability, DiaSys constantly expands its product portfolio, which comprises reagents for routine and special diagnostics, as well as fully automated and semi-automated clinical chemistry analyzers, POCT instruments and water purification systems.

 Press Releases

• Total bile acids 21 FS - now applicable for human stool samples (Jun 05, 2023)

  In October 2019, DiaSys successfully introduced Total bile acids 21 FS to determine total bile acids in serum.

  Without altering the reagent composition and the highly sensitive enzymatic cycling method, DiaSys now extends this reagent with regard to detecting total bile acids in human stool samples.

  Total bile acids (TBA) determination in stool plays a major role in the diagnosis of gastrointestinal tract disorders, such as irritable bowel syndrome with diarrhea (IBS-D), bile acid diarrhea (BAD) or Crohn’s disease. Approximately 25 – 50% of patients with IBS-D display increased total fecal bile acids. Furthermore, BAD is a common cause of chronic unexplained diarrhea.

  Even though IBS-D and BAD occur worldwide, the gold standard diagnosis method (⁷⁵SeHCAT test) is not licensed in some countries and not common in standard clinical laboratories. The time span for this test is seven days, which is inconveniently time-consuming. Moreover, patients undergoing this test have to ingest a radioactive substance, which is another disadvantage of this method. Alternative methods, such as LC-MS or GC-MS, are technically complex.

  Total bile acids 21 FS is conveniently applicable on all clinical chemistry analyzers. The liquid-stable, ready-to-use DiaSys reagent has a wide measuring range (up to 130 µmol/L), good precision and long onboard and calibration stability. It shows good reproducibility and minimal interference from endogenous substances that may interfere.

  More on: https://www.total-bile-acids.com/

• Procalcitonin FS: Now available in dedicated kits for DiaSys respons® systems and BioMajesty® JCA-BM6010/C (Jun 05, 2023)

  Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection. It is a global health concern, affecting an estimate of 48.9 million people each year.

  DiaSys Procalcitonin FS has been successfully marketed since 2020. It is a particle enhanced immunoturbidimetric assay to determine procalcitonin in serum and plasma on automated photometric systems and offers a reliable alternative, when time matters in sepsis management.

  The assay offers high precision at clinical cut-off levels and a measuring range from 0.27 (depending on the analyzer) to 50 ng/mL. No prozone effect is observed up to 1000 ng/mL. Furthermore, Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management.                                                                                       

  In addition to the system kit, Procacitonin FS is now available in dedicated kits for DiaSys respons^® systems and BioMajesty^® JCA-BM6010/C. DiaSys also offers dedicated calibrators and controls.

  During AACC, a scientific poster will be submitted which proves that DiaSys Procalcitonin FS offers a solution to the current landscape of deviating PCT measuring results.

  https://www.diasys-diagnostics.com/products/reagents/immunoturbidimetry/reagent-details/227-procalcitonin-fs/reagent.show

• Implementation of e-labeling (Jun 05, 2023)

  he primary mechanism by which the diagnostics industry provides product information to healthcare professionals consists in package inserts and instructions for use (IFUs). Revisions of these documents, which may occur more than once a year, are time consuming, and involve a delay between updating and making it available to users. 

  Thus, DiaSys has decided to discontinue the familiar paper form of package inserts and is switching to so-called e-labeling, i.e. electronic labeling.

  In future, all DiaSys package inserts and IFUs will only be made available via the newly introduced search function on the website.

  Package inserts for point-of-care (e.g. HbA1c IS), calibrators, controls, or value sheets are not submitted to e-labeling.

  In parallel with the ongoing clearance sale of stock, kit labels of all newly produced kits will gradually bear the corresponding link diasys.com/doc, leading to the search mask.

  In addition to dropping costly re-printing of hard copies, DiaSys will reduce their ecological footprint and will be in a position to make all necessary updating available immediately for all users.

• DiaSys own AACC website (Jun 12, 2023)

  Find out more on DiaSys, their portfolio, and participation at AACC 2023: 

  https://www.diasys-diagnostics.com/service-area/aacc-2023. 

 Additional Info